Research Library › Peptide Fragments
TB-500 is a synthetic, acetylated seven-amino-acid peptide (LKKTETQ) that reproduces the actin-binding segment of thymosin beta-4, a naturally occurring 43-amino-acid protein first isolated from calf thymus. Thymosin beta-4 was characterized in Allan L. Goldstein’s laboratory, which published its full sequence in 1981, and the short fragment traces to a 2003 study. As of 22 Oct 2026 neither TB-500 nor thymosin beta-4 is FDA-approved.
Key facts
| Type | Synthetic 7-amino-acid peptide with an acetyl cap |
|---|---|
| Sequence | Ac-LKKTETQ (Leu-Lys-Lys-Thr-Glu-Thr-Gln) |
| Derived from | Thymosin beta-4, a natural 43-amino-acid protein first isolated from calf thymus |
| First described | Thymosin beta-4 sequenced 1981; actin-binding fragment studied 2003 |
| Developed by | Allan L. Goldstein (George Washington University; founder of RegeneRx), with Hynda Kleinman's group for the 2003 fragment work |
| Designed target | Actin, the cytoskeletal protein involved in cell movement |
| Regulatory status (Oct 2026) | Not FDA-approved; PCAC voted 8–6–1 on TB-500 compounding in July 2026; no final FDA decision |
Who developed it
Thymosin beta-4 was discovered by Allan L. Goldstein, former chair of biochemistry at George Washington University. In 1982 he founded the company now known as RegeneRx Biopharmaceuticals [1, 2]. His laboratory published the protein’s complete amino acid sequence in 1981 [3].
TB-500 traces back to a 2003 paper co-authored by Goldstein and Hynda Kleinman’s group. That study compared the full protein with a synthetic peptide containing only its actin-binding domain [4, 5].
What it was designed to target
Thymosin beta-4 is a natural 43-amino-acid protein first extracted from calf thymus [3]. Biochemists later showed it is identical to Fx, a peptide that binds and sequesters actin, the protein that forms the internal scaffolding cells use to change shape and move [6].
TB-500 is a lab-made copy of just seven of those 43 amino acids, LKKTETQ, with an acetyl group capping one end. It was designed to represent the actin-binding region of the parent protein. The FDA’s 2026 briefing document states plainly that TB-500 and thymosin beta-4 are not the same substance [5].
Why it was created
Thymosin beta-4 was first described as a thymic hormone associated with the maturation of immune cells [3]. Research interest later shifted toward tissue repair: by 2001 RegeneRx had licensed rights from the US National Institutes of Health to develop the protein as a tissue repair factor [2].
RegeneRx’s lead program, RGN-259, is an eye-drop formulation of the full-length protein originally investigated in a research program on corneal conditions [2]. A larger corneal trial, SEER-2, has finished, with topline results targeted for mid-November 2026 [7]. The FDA’s 2026 review found no published articles in which TB-500 itself was given to people; all human studies used the full protein [2, 5].
Research timeline
- 1981: Full amino acid sequence of thymosin beta-4 published [3]
- 1982: Goldstein founds the company now called RegeneRx [1]
- 1991: Thymosin beta-4 shown to be identical to the actin-sequestering peptide Fx [6]
- 2001: RegeneRx licenses NIH rights for tissue repair research [2]
- 2003: Synthetic actin-binding fragment studied in mice [4]
- July 2026: FDA advisory committee votes 8–6, with one abstention, on TB-500 [8, 9]
Regulatory status as of October 2026
Neither TB-500 nor thymosin beta-4 is approved as a drug in the United States or elsewhere. In April 2026 the FDA removed TB-500 from its Category 2 list of bulk substances that raise significant safety concerns for compounding [10].
On 23–24 July 2026 the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8–6, with one abstention, to recommend allowing pharmacy compounding of TB-500 for the nominated use under review, contrary to FDA staff’s recommendation [5, 8, 11]. The vote is advisory, and any list change requires rulemaking [8]. As of 22 Oct 2026 the FDA had made no final decision. On 14 Oct 2026 an FDA interim access policy for compounding certain peptides went to the White House for review [12].
The 2026 WADA Prohibited List names “thymosin-β4 and its derivatives e.g. TB-500” under section S2 [13].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a natural 43-amino-acid protein, while TB-500 is a synthetic seven-amino-acid fragment (Ac-LKKTETQ) of it. The FDA states they are not the same substance [5].
Who discovered thymosin beta-4?
Allan L. Goldstein, then at George Washington University, discovered thymosin beta-4; his laboratory published its full sequence in 1981 [1, 3].
Is TB-500 FDA approved?
No. As of 22 Oct 2026 TB-500 is not FDA-approved. An FDA advisory committee voted on its compounding status in July 2026, but no final decision has been issued [8, 11].
Has TB-500 been studied in humans?
The FDA’s 2026 review found no published articles in which TB-500 was administered to people. Human clinical studies have used the full thymosin beta-4 protein [5].
Sources
- RegeneRx Biopharmaceuticals. Proxy statement (DEF 14A), director biography of Allan L. Goldstein. SEC, filed 10 Aug 2015. Link
- RegeneRx Biopharmaceuticals. Annual report (Form 10-K) for fiscal 2022. SEC, filed 11 Apr 2023. Link
- Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981. PMID 6940133. Link
- Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic and aged mice. Wound Repair Regen. 2003. PMID 12581423. Link
- U.S. FDA. Briefing document: TB-500 (free base) and TB-500 acetate, Pharmacy Compounding Advisory Committee, 23–24 Jul 2026 (dated 15 May 2026). Link
- Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991. PMID 1999398. Link
- RegeneRx Biopharmaceuticals. Letter to stockholders (SEER-2 update from HLB Therapeutics), 1 Sep 2026. Link
- McDermott Will & Schulte. Bulk list bound: PCAC backs majority of peptides in two-day public meeting. 27 Jul 2026. Link
- Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
- Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
- Buchanan Ingersoll & Rooney. FDA advisory committee voted yes on six peptides. Now what? 18 Aug 2026. Link
- Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
- World Anti-Doping Agency. 2026 Prohibited List (S2 names thymosin-β4 and derivatives e.g. TB-500). Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
